Contact: Courtney Covington 517-335-7666Agency: Attorney General
August 7, 2020
LANSING – Michigan Attorney General Dana Nessel has joined a bipartisan coalition in sending a letter request to the U.S. Health and Human Services (HHS), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA), urging them to use their legal authority under the Bayh-Dole Act to increase the availability of the prescription drug, remdesivir. Remdesivir, a drug manufactured by Gilead Sciences Inc. (Gilead), has shown promising results in reducing mortality and hospitalization from COVID-19.
Remdesivir is an FDA fast-tracked antiviral drug that was produced with the benefit of millions of dollars of federal funding and the time and expertise of CDC and military scientists. Despite the substantial federal funding provided to its manufacturer, Gilead has been unable to assure a supply of remdesivir sufficient to alleviate the health and safety needs of the country amid the pandemic.
"Mounting scientific data is showing that remdesivir can benefit those battling COVID-19, and the federal government should want to do everything in its power to ensure it is accessible to all who need it," said Nessel. "My colleagues and I are urging these agencies to use their legal authority to guarantee widespread access to this prescription drug, and make certain that it is not only available to those with deep pockets or political connections, but everyone whose health is strained by this pandemic. This nation and the entire world is in the middle of a crisis and if the federal government isn't going to exercise its authority to address the current and unconscionable $3,200 price tag Gilead has set per treatment course, then we ask them to assign such authority to the states."
More on Michimich.com
As of Aug. 3, 2020, more than 4.64 million Americans have contracted COVID-19 and 154,000 have died. Yet, by the end of this year, Gilead is expected to produce only two million treatments, or enough remdesivir to cover about half of the current confirmed COVID-19 patients in the U.S. Before this crisis is over and a vaccine is made available, many more Americans may become sick, and their recovery may hinge on the availability and affordability of remdesivir.
In Tuesday's letter, the bipartisan coalition urges the federal government to exercise its rights under the Bayh-Dole Act, which allows the NIH and FDA to ensure Americans can afford and have reasonable access to a sufficient supply of remdesivir during this pandemic. Despite a manufacturing cost of between $1 and $5, Gilead has set the price of the drug at an outrageous and unconscionable $3,200 per treatment course. Under the Bayh-Dole Act, the NIH and FDA has the authority to license remdesivir to third-party manufacturers to scale up production and distribution and ensure the drug is made available to all those in need at a reasonable price. If these agencies are unwilling to exercise this authority, the states request that the agencies assign this authority for the states to use. The bipartisan coalition stands ready to ensure that drug manufacturers are licensed to meet market demand during this public health crisis.
More on Michimich.com
Nessel joins the attorneys general of Alaska, American Samoa, California, Connecticut, Delaware, the District of Columbia, Guam, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont, Virginia, and Washington in sending this letter.
A copy of the letter is available here.
August 7, 2020
LANSING – Michigan Attorney General Dana Nessel has joined a bipartisan coalition in sending a letter request to the U.S. Health and Human Services (HHS), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA), urging them to use their legal authority under the Bayh-Dole Act to increase the availability of the prescription drug, remdesivir. Remdesivir, a drug manufactured by Gilead Sciences Inc. (Gilead), has shown promising results in reducing mortality and hospitalization from COVID-19.
Remdesivir is an FDA fast-tracked antiviral drug that was produced with the benefit of millions of dollars of federal funding and the time and expertise of CDC and military scientists. Despite the substantial federal funding provided to its manufacturer, Gilead has been unable to assure a supply of remdesivir sufficient to alleviate the health and safety needs of the country amid the pandemic.
"Mounting scientific data is showing that remdesivir can benefit those battling COVID-19, and the federal government should want to do everything in its power to ensure it is accessible to all who need it," said Nessel. "My colleagues and I are urging these agencies to use their legal authority to guarantee widespread access to this prescription drug, and make certain that it is not only available to those with deep pockets or political connections, but everyone whose health is strained by this pandemic. This nation and the entire world is in the middle of a crisis and if the federal government isn't going to exercise its authority to address the current and unconscionable $3,200 price tag Gilead has set per treatment course, then we ask them to assign such authority to the states."
More on Michimich.com
- Michigan: Key energy assistance deadlines nearing as home heating season approaches; learn ways to help keep winter utility bills manageable
- Michigan: Treasury: More Options Coming for Returning Bottles, Cans
- Michigan: First military and overseas voter ballots mailed Saturday, federal write-in option available in event of postal delays
- Michigan: Final Adopt-A-Highway cleanup of year starts Saturday
- North American International Auto Show Moves Reimagined Show to September 2021 and Beyond
As of Aug. 3, 2020, more than 4.64 million Americans have contracted COVID-19 and 154,000 have died. Yet, by the end of this year, Gilead is expected to produce only two million treatments, or enough remdesivir to cover about half of the current confirmed COVID-19 patients in the U.S. Before this crisis is over and a vaccine is made available, many more Americans may become sick, and their recovery may hinge on the availability and affordability of remdesivir.
In Tuesday's letter, the bipartisan coalition urges the federal government to exercise its rights under the Bayh-Dole Act, which allows the NIH and FDA to ensure Americans can afford and have reasonable access to a sufficient supply of remdesivir during this pandemic. Despite a manufacturing cost of between $1 and $5, Gilead has set the price of the drug at an outrageous and unconscionable $3,200 per treatment course. Under the Bayh-Dole Act, the NIH and FDA has the authority to license remdesivir to third-party manufacturers to scale up production and distribution and ensure the drug is made available to all those in need at a reasonable price. If these agencies are unwilling to exercise this authority, the states request that the agencies assign this authority for the states to use. The bipartisan coalition stands ready to ensure that drug manufacturers are licensed to meet market demand during this public health crisis.
More on Michimich.com
- Community First Health Plans Announces Theresa Scepanski as President and Chief Executive Officer
- Michigan: US-127 resurfacing in Ingham County begins today
- Michigan Civil Rights Commission Issues Statement on the Passing of Justice Ruth Bader Ginsburg
- AUA College of Medicine Partners with Fisk University
- 2020 Hurricane Season Squeezing Supplies of Tarps and Industrial Grade Coverings
Nessel joins the attorneys general of Alaska, American Samoa, California, Connecticut, Delaware, the District of Columbia, Guam, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont, Virginia, and Washington in sending this letter.
A copy of the letter is available here.
0 Comments
Latest on Michimich.com
- Michigan: MDARD updates state's two hemlock woolly adelgid quarantines
- Michigan: Weigh in on strategy for more than 4 million acres of public lands at virtual public meetings Sept. 30, Oct. 1
- ComForCare and At Your Side Home Care Hosts Fall Prevention Webinar on First Day of Fall
- The Black Women's Roundtable "Take It To The Top Entrepreneurship Challenge" for Black Women & Girls
- Mango Animate Unveils an Animation Maker for Everyone
- Michigan: M-30 reopens over the Tittabawassee River to local traffic in Edenville today
- 'Sensual' is Out and Fans Go Ecstatic Seeing Heather Fay at Her Best
- Michigan: EGLE issues emergency work order for Edenville Dam safety measures
- Statement from Michigan Department of State spokesperson Jake Rollow on President Trump's inaccurate tweet
- Michigan: Notification of Medical Marijuana Product Recall
- Michigan: I-94 and M-60 lane closures for beam setting in Jackson begin on Wednesday
- MDARD provides list of licensed mosquito spraying companies in Michigan
- Michigan: Dearborn Man Seeking $9.8M Tax Return Heading to Circuit Court
- Michigan: AG Nessel Joins 22-State Coalition Urging USDA to Remove Bureaucratic Barriers Threatening SNAP During Pandemic
- Wild Weekend Planned for Int'l Wild Bunch Film Fest in Willcox Arizona, Oct 2/4
- AUA announces Master of Public Health Collaboration with FIU Stempel College to allow students to pursue both medical and public health degrees
- AcadianKitchens.com Launches With Free Shipping on the Best Cajun Food in the Country
- Michigan Psychological Care Offers Relationship Counseling in Response to COVID Stress
- Michigan: Details of first two virtual opioids town halls announced; events are September 23 and 25
- Michigan: Treasury: Scammers Using Fake Letters in Collections Scam